Novavax Inc., a clinical-stage vaccine company that specializes on discovering, creating and commercializing recombinant nanoparticle vaccines and adjuvants, recently announced that it has chosen added Gail Boudreaux to the company’s board of directors.
Boudreaux attended Dartmouth College for her bachelor’s degree in psychology, and earned her Master of Business Administration in finance and health care administration at Columbia Business School. She has previously worked at UnitedHealth Group as the executive president between May 2008 and February 2015 and chief executive officer between January 2011 and November 2014. She brings over 30 years of experience from a variety of health care operations with her to Novavax.
“I am very happy to be joining Novavax at such an exciting time,” Boudreaux said. “I look forward to helping the company achieve its goal to develop and deliver safe and effective vaccines to improve global heath.”
Boudreaux is also the director of Zimmer Holdings Inc. and Xcel Energy Inc, and is a trustee at Dartmouth College.
“We are delighted to welcome Gail to Novavax's Board,” Stanley Erck, president and CEO of Novavax, said. “Her outstanding leadership and business experience will be important to our continued growth and success. Gail’s insight on health payers will be particularly important as we continue to move towards commercialization of our vaccines.”